{"id":564922,"date":"2021-09-21T17:10:02","date_gmt":"2021-09-21T17:10:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=564922"},"modified":"2021-09-21T17:10:02","modified_gmt":"2021-09-21T17:10:02","slug":"key-players-such-as-pharnext-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-charcot-marie-tooth-market","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/key-players-such-as-pharnext-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-charcot-marie-tooth-market_564922.html","title":{"rendered":"Key players such as Pharnext and others are developing therapies to enhance treatment modalities in the Charcot Marie Tooth market"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1632222406.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Key players such as Pharnext and others are developing therapies to enhance treatment modalities in the Charcot Marie Tooth market\" src=\"https:\/\/www.abnewswire.com\/uploads\/1632222406.png\" alt=\"Key players such as Pharnext and others are developing therapies to enhance treatment modalities in the Charcot Marie Tooth market\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Charcot Marie Tooth Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveIsight\u2019s Charcot Marie Tooth market report offers detailed information on the Charcot Marie Tooth disease, historical and epidemiology forecasted epidemiology, and Charcot Marie Tooth market trends in the 7MM.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/5be1713d8fb14fb26c7e0afb778f2cb5.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveIsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/charcot-marie-tooth-disease-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Charcot Marie Tooth market report<\/a><\/strong> offers detailed information on the Charcot Marie Tooth disease, historical and epidemiology forecasted epidemiology, and Charcot Marie Tooth market trends in the 7MM (the US, EU5 (France, Spain, Italy, the UK, and Germany), and Japan).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Takeaways from the Charcot Marie Tooth Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per DelveInsight&rsquo;s estimate, the total Charcot Marie Tooth prevalence was <strong>263,835<\/strong> in the 7MM in 2020, which is expected to rise even more by 2030<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Among the EU5 countries, <strong>France<\/strong> has the highest Charcot Marie Tooth diagnosed prevalence while Spain had the least in 2020.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per DelveInsight&rsquo;s Charcot Marie Tooth epidemiology analysis, <strong>males<\/strong> had the highest number of CMT cases than <strong>females<\/strong> in the 7MM in 2020.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Charcot Marie Tooth market size was found to be <strong>USD 55 million<\/strong> in the 7MM in 2020.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leading pharmaceutical companies such as <strong>Pharnext<\/strong> and others are working on their lead assets to improve the Charcot Marie Tooth treatment landscape.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key CMT therapies in the pipeline include <strong>PXT3003<\/strong> and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>PXT3003<\/strong>, a novel, synergistic, low-dose fixed combination of baclofen (a muscle relaxant), naltrexone (an opioid antagonist), and sorbitol (a laxative) given twice daily as an oral solution, is being developed by <strong>Pharnext<\/strong>. It was developed using Pharnext&#8217;s R&amp;D platform, Pleotherapy, and has Orphan Drug Designation in the EU and the US.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Request a sample to learn more about the CMT treatment landscape @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/charcot-marie-tooth-disease-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Charcot Marie Tooth Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Charcot Marie Tooth Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Charcot Marie Tooth (CMT) is a disease of the peripheral nerves that control muscles. It is a group of genetically diverse disorders that affect the motor and peripheral sensory nerves, causing muscle weakness, atrophy, and sensory loss.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Charcot Marie Tooth Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Charcot Marie Tooth report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Charcot Marie Tooth Total Prevalent Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Charcot Marie Tooth Diagnosed Prevalent Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Charcot Marie Tooth Gender-Specific Diagnosed Prevalent Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Charcot Marie Tooth Age-Specific Diagnosed Prevalent Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Charcot Marie Tooth Type-Specific Diagnosed Prevalent Cases<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Charcot Marie Tooth Therapeutics Market<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Charcot Marie Tooth has no cure and no approved therapies. The current CMT therapeutic market is based on supportive and symptomatic management, such as occupational therapies, physiotherapy, ankle-foot orthoses (AFO), and shoe inserts. Physiotherapy is the most commonly used aid, followed by foot care and occupational therapy.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Charcot Marie Tooth Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Increased awareness of this distinct histology has resulted in developing drugs specific to Charcot Marie Tooth (CMT). It has begun to shed light on the similarities and possible differences. These factors and the anticipated introduction of new therapies such as <strong>PXT3003<\/strong> will drive the CMT market during the forecast period (2021&ndash;2030).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Find out more about the market trends @<strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/charcot-marie-tooth-disease-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Charcot Marie Tooth Market Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Charcot Marie Tooth Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">PXT3003: Pharnext<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Charcot Marie Tooth Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Potential therapies&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Awareness and knowledge<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Increasing prevalence<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Limited competition for upcoming therapies<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Charcot Marie Tooth Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Challenging disease in terms of diagnosis and management<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">High diagnostic cost<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lack of robust pipeline<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">High disease burden<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope for the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage:<\/strong> 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Study Period:<\/strong> 2018-30<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Charcot Marie Tooth Key Companies:<\/strong> Pharnext, among others.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Charcot Marie Tooth Key Pipeline Therapies:<\/strong> PXT3003, and others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Charcot Marie Tooth Segmentation:<\/strong> By Geography, By Charcot Marie Tooth therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis:<\/strong> Comparative and conjoint analysis of Charcot Marie Tooth emerging therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Tools Used:<\/strong> SWOT Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Case Studies<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>KOL&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analyst&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"93\" \/>\n<col width=\"531\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Key Insights<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Charcot&ndash;Marie&ndash;Tooth (CMT) Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Charcot&ndash;Marie&ndash;Tooth (CMT) Market: Future Perspective<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Executive Summary of Charcot&ndash;Marie&ndash;Tooth (CMT)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Key Events<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Charcot&ndash;Marie&ndash;Tooth: Disease Background and Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">CMT Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Patient Journey<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Organizations contributing towards Charcot Marie Tooth Disease<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">11.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">CMT Emerging Drugs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Charcot&ndash;Marie&ndash;Tooth (CMT): Seven Major Market Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">13.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">KOL Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">14.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">CMT Market Drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">15.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">CMT Market Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">16.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">17.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">CMT Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">18.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">CMT Reimbursement and Market Access<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">19.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">20.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">21.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">22.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">For rich insights into Healthcare and Pharmaceutical News, visit <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare, and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dravet-syndrome-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Dravet Syndrome Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get a comprehensive analysis of Dravet Syndrome pipeline therapies and key companies such as B<strong>iocodex, GW Pharmaceuticals, Zogenix, Ovid Therapeutics, PTC Therapeutics, among others.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=key-players-such-as-pharnext-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-charcot-marie-tooth-market\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=key-players-such-as-pharnext-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-charcot-marie-tooth-market\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Charcot Marie Tooth Market DelveIsight\u2019s Charcot Marie Tooth market report offers detailed information on the Charcot Marie Tooth disease, historical and epidemiology forecasted epidemiology, and Charcot Marie Tooth market trends in the 7MM. DelveIsight&rsquo;s Charcot Marie Tooth market report offers &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/key-players-such-as-pharnext-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-charcot-marie-tooth-market_564922.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-564922","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/564922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=564922"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/564922\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=564922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=564922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=564922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}